GSK plc's RSV vaccine, Arexvy, has received Japan's regulatory application approval for use in adults aged 18-49 at increased risk of severe disease, with positive Phase IIIb data supporting this expansion. The event was announced on June 20, 2025, and marks a significant advancement for GSK in addressing public health needs.